Latest Morning Briefing Stories
Must-Reads Of The Week From Brianna Labuskes
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
Podcast: KHN’s ‘What The Health?’ Drug Prices And Unicorns
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico, and Erin Mershon of Stat News discuss a series of health policy court decisions on everything from prescription drug discounts to soda taxes. Plus, Rovner, interviews health care futurist and consultant Jeff Goldsmith.
Staggering Prices Slow Insurers’ Coverage Of CAR-T Cancer Therapy
Some state Medicaid programs are not paying for the procedures, and Medicare’s complicated payment rates have hospitals concerned that it will not cover all the costs.
Podcast: KHN’s ‘What The Health?’ ACA Under Fire. Again.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Julie Appleby of Kaiser Health News discuss the health politics of the latest Supreme Court pick, as well as the Trump administration’s efforts to further undermine the Affordable Care Act. Plus, for extra credit, the panelists recommend their favorite health stories of the week.
Podcast: KHN’s ‘What The Health?’ Whither Work Requirements?
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Stephanie Armour of The Wall Street Journal and Anna Edney of Bloomberg News discuss the latest enrollment numbers for the Affordable Care Act, Medicaid work requirements in Kentucky and President Donald Trump’s proposed government reorganization plan. Plus, for extra credit, the panelists recommend their favorite health stories of the week.
Gastos de bolsillo impiden que más personas reciban la droga que previene el VIH
Funcionarios de salud pública están intensificando esfuerzos para que más personas puedan consumir PrEP. Pero aseguradoras ponen trabas al uso de cupones.
Out-Of-Pocket Costs Put HIV Prevention Drug Out Of Reach For Many At Risk
It’s getting increasingly difficult for patients to afford Truvada, also known as pre-exposure prophylaxis, or PrEP, because of the drug’s high price and insurance company efforts to restrict the use of coupons that shield patients from it.
Must-Reads Of The Week From Brianna Labuskes
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
Top Policy Expert’s Ties To Giant Drugmaker Often Go Unstated
Dr. Mark McClellan joined Johnson & Johnson’s board of directors after leaving the FDA, but the connection often isn’t mentioned in research papers or public events.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes, who reads everything on health care to compile our daily Morning Briefing, offers the best and most provocative stories for the weekend.
Purdue And The OxyContin Files
Purdue Pharma planned an extensive marketing campaign for the launch and promotion of the painkiller OxyContin. Here are Purdue’s internal budget documents from 1996 to 2002 — files released by the Florida attorney general’s office — that detail the company’s early strategy to sell and expand use of the drug.
How America Got Hooked On A Deadly Drug
An inside look at how Purdue Pharma pushed OxyContin despite risks of addiction and fatalities.
Medicamentos de Medicare pueden costar menos pagando en efectivo
Beneficiarios de Medicare pueden conseguir medicamentos más baratos si pagan en efectivo… pero por reglas mordaza el farmacéutico no puede decirlo.
Looking For Lower Medicare Drug Costs? Ask Your Pharmacist For The Cash Price.
Sometimes a drug plan’s copayment is higher than the cash price, and under a little-known federal rule, pharmacists have to tell Medicare beneficiaries that — but only if they ask.
Benefit Change Could Raise Costs For Patients Getting Drug Copay Assistance
More health plans are refusing to count the copayment assistance offered by drug makers as part of the patients’ deductibles or out-of-pocket limits.
Best Reads Of The Week With Brianna Labuskes
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
Podcast: KHN’s ‘What The Health?’ Campaign Promises Kept, Plus ‘Nerd Reports’
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Sarah Kliff of Vox and Alice Ollstein of Talking Points Memo discuss a proposed administration regulation that seeks to separate Planned Parenthood from federal family planning funds, the final congressional passage of legislation aimed at helping those with terminal illnesses obtain experimental medications, and new government reports on the uninsured and federal health spending. Also, Rovner interviews KHN’s Liz Szabo about the May “Bill of the Month.”
Pfizer Settles Kickback Case Related To Copay Assistance For $24M
The drugmaker agreed to a settlement with the Justice Department over allegations that it funneled copay assistance money through a foundation to Medicare patients.
Watch: What’s In The White House Plan To Lower Drug Prices
KHN’s Sarah Jane Tribble explains the key elements of the Trump blueprint on CBS News’ “Red & Blue.”
Drugmakers Blamed For Blocking Generics Have Jacked Up Prices And Cost U.S. Billions
The Trump administration is shaming brand-name drugmakers who refuse to sell samples so generics can be made from their products.
